Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07677059
PHASE2

A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study

Sponsor: Kymera Therapeutics, Inc.

View on ClinicalTrials.gov

Summary

This Phase 2b open-label, long-term extension study is designed to evaluate the long-term safety and efficacy of KT-621 in participants with asthma who were previously enrolled in the parent study (KT621-AS-202) of KT-621 for asthma. The main goals of this study are to investigate the long-term safety and tolerability of KT-621, the long-term efficacy of KT-621 at treating asthma, and how KT-621 behaves in the body long-term.

Official title: A Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Safety and Tolerability of KT-621 in Participants With Asthma Previously Enrolled in a KT-621 Asthma Study

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

264

Start Date

2026-06-25

Completion Date

2028-12

Last Updated

2026-10-07

Healthy Volunteers

No

Interventions

DRUG

KT-621

Oral drug

Locations (7)

Kymera Investigative Site

Miami, Florida, United States

Kymera Investigative Site

Tampa, Florida, United States

Kymera Investigative Site

Dallas, Texas, United States

Kymera Investigative Site

Berlin, Germany

Kymera Investigative Site

Poznan, Poland

Kymera Investigative Site

Kamenitz, Serbia

Kymera Investigative Site

Užice, Serbia